Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIM Dietary Supplementation for CIN
NCT00212381Phase 3Completed
- Sponsor
- NewYork-Presbyterian Hospital
- Start
- Sep 2000
- Primary completion
- Jan 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of 3,3'-diindolylmethane in cervical intraepithelial neoplasia (CIN), sponsored by NewYork-Presbyterian Hospital. Started Sep 2000; status: completed.
02
Drugs
3,3'-diindolylmethane
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on NCT00212381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00212381.